{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:41:03Z","timestamp":1789062063326,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jaad.2021.05.050","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T08:22:06Z","timestamp":1623831726000},"page":"847-853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study"],"prefix":"10.1016","volume":"85","author":[{"given":"Brett","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Forman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"McCollam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gamalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Janes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Edson-Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Holzwarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Dutronc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2021.05.050_bib1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jaad.2018.01.048","article-title":"Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families","volume":"79","author":"Liu","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.05.050_bib2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjd.14497","article-title":"Alopecia areata and health-related quality of life: a systematic review and meta-analysis","volume":"175","author":"Rencz","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.050_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.jaad.2016.04.035","article-title":"Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review","volume":"75","author":"Liu","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.050_bib4","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jaad.2017.09.011","article-title":"Alopecia areata is a medical disease","volume":"78","author":"Korta","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2021.05.050_bib5","first-page":"304370","article-title":"Prevalence of psychological disorders in patients with alopecia areata in comparison with normal subjects","volume":"9","author":"Aghaei","year":"2014","journal-title":"ISRN Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.050_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.05.050_bib7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2019.08.032","article-title":"Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis","volume":"82","author":"Lee","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.050_bib8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.autrev.2014.10.014","article-title":"The autoimmune basis of alopecia areata: a comprehensive review","volume":"14","author":"Islam","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.jaad.2021.05.050_bib9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4103\/ijt.ijt_99_17","article-title":"Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options","volume":"10","author":"Darwin","year":"2018","journal-title":"Int J Trichology"},{"key":"10.1016\/j.jaad.2021.05.050_bib10","doi-asserted-by":"crossref","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","article-title":"Alopecia areata","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaad.2021.05.050_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaut.2018.12.001","article-title":"Alopecia areata: a multifactorial autoimmune condition","volume":"98","author":"Simakou","year":"2019","journal-title":"J Autoimmun"},{"issue":"12","key":"10.1016\/j.jaad.2021.05.050_bib12","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2021.05.050_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.050_bib14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBiomedicine"},{"issue":"15","key":"10.1016\/j.jaad.2021.05.050_bib15","doi-asserted-by":"crossref","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.jaad.2021.05.050_bib16","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.jaad.2021.05.050_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","article-title":"Tofacitinib for the treatment of alopecia areata and variants in adolescents","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2021.05.050_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2021.05.050_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jdcr.2019.07.005","article-title":"Treatment of severe alopecia\u00a0areata with baricitinib","volume":"5","author":"Olamiju","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2021.05.050_bib20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bjd.18883","article-title":"The alopecia areata investigator global assessment scale: a measure for evaluating clinically meaningful success in clinical trials","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2021.05.050_bib21","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","article-title":"Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2021.05.050_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/bjd.19024","article-title":"Development of the scalp hair assessment PRO measure for alopecia areata","volume":"183","author":"Wyrwich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2021.05.050_bib23","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","article-title":"Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata","volume":"21","author":"Wyrwich","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jaad.2021.05.050_bib25","first-page":"3","article-title":"3rd Inflammatory Skin Disease Summit-The translational revolution December 12-15, 2018 Vienna, Austria (Abstract 125)","volume":"27","year":"2018","journal-title":"Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221010884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962221010884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:01:28Z","timestamp":1759273288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962221010884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0190962221010884"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2021.05.050","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2021.05.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}